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HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS STEM CELL TRANS-
PLANTATION IN 61 PATIENTS WITH LIGHT CHAIN AMYLOIDOSIS: A
SINGLE CENTRE EXPERIENCE
Schonland, S.O.1, Dengler, J.B.1, Bochtler, T.1, Goldschmidt, H.1,
Ho, A.D.1, Hegenbart, U.1 1Univ. of Heidelberg, Med. Department,
Div. of Hematology/Amyloidosis Clinic, Heidelberg, Germany.
Introduction:High-dose chemotherapy (HDC) with autologous
hematopoietic stem cell transplantation (ASCT) is currently the
treatment which induces the highest rates of remission in patients
(pts) with light chain amyloidosis (AL). Due to impaired organ
function in these pts a high treatment-related mortality (TRM) up
to 40% has been published. A high TRM was also noted in a
French multicenter phase III study which compared melphalan /
dexamethasone chemotherapy with HD melphalan. As a conse-
quence no advantage of HDC could be observed in this trial so far
(ASH 2005).
Methods: We have retrospectively analyzed all pts with AL who
received HDC (HD melphalan median 200 mg/m2, range 70-200
in 60 pts and HD-BEAM in 1pt) and ASCT in our centre from
1998 until 2006.
Results: We report on 61 patients (median age 57 years, range
35-69; n7 with multiple myeloma stage I and 1 pt with Walden-
stroms disease) treated with HDC and ASCT in our institution
with a follow up of more than 3 months. Exclusion criteria were
age 70 years, symptomatic heart involvement  NYHA stage II
and WHO performance status 2. The median number of in-
volved organs was 2 (1-5). 5 pts had end stage renal failure at time
of transplant. The median follow-up is 23 months (range, 9 days -
100 months). Complete hematological remission was obtained in
26 out of 54 (48%) and organ response in 22 out of 56 evaluable
patients (39%). In further 31 patients organ function has stabilized
(55%). 48 out of 61 pts are alive (79%), 2 pts died of TRM (3%).
Estimated overall survival at 2 and 4 years is 80% and 66%,
respectively. Hematological relapse or progression occurred in 10
patients (19%) at a median of 27 months. There was a signiﬁcant
difference regarding OS between pts in CR vs. non-CR (p0.001).
Organ progression was noted only in 5 pts with CR and in 15 pts
not reaching CR and occurred later in CR pts (P0.001).
Discussion: HDC is in our view currently the treatment of
choice for pts who are highly selected to be eligible for this
treatment. Here we conﬁrm that high overall response and survival
rates can be achieved with a low TRM in a single institution with
a large experience in AL amyloidosis. The main goal remains
achievement of a CR as organ progression can be prevented in
these pts. Further therapeutic strategies have to focus on non-CR
pts using new drugs effective in the treatment of multiple my-
eloma.
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IMPLICATIONS OF BODY WEIGHT CALCULATIONS FOR AUTOLOGOUS
PERIPHERAL BLOOD STEM CELL TRANSPLANTATION
Simpson, L.1, Wolfe, R.C.1, Gastineau, D.A.1, Hogan, W.J.1,
Kumar, S.1 1Mayo Clinic, Rochester, MN.
Background: BMI varies greatly among autologous stem cell
transplantation (SCT) recipients. Stem cell collection targets are
usually determined using actual body weight (ABW). Conditioning
chemotherapy doses usually use corrected ideal body weight
(IBW). Since stemcells home to bone marrow, the IBW being
based on the height may better indicate stemcell numbers required
than ABW. Since chemotherapy doses are calculated based on
corrected IBW, and the volume of distribution is higher in obese
patients, these patients may have decreased drug exposure and
higher progression risk.
Methods: Retrospective, single institution evaluation of engraft-
ment kinetics and outcomes of 306 SCTs done between 1998 and
2001 was performed. SCT reasons were myeloma (46%), NHL
(34%), HD (6%) and AL amyloidosis (14%). The stem cell doses
were calculated based on ABW and IBW and correlated with time
to WBC and platelet engraftment. We also evaluated the effect of
BMI on the PFS after SCT using various cutoffs.
Results: The mean (range) of ABW, IBW and BMI were 46.6 kg
to 189 Kg; 45.5 kg to 94 kg; and 17.5 to 55.8 respectively. Using
logistic regression, we estimated the CD34 cell dose by ABW and
IBW that best predicts platelet engraftment (50,000) by day 21
post transplant. The coefﬁcients for both doses were similar (Ideal
0.391; Actual 0.361).Using ROC analysis; we determined the stem
cell dose cutoff that best predicted for failure to engraft neutrophils
by 21 days post transplantation, median CD34 dose by ABW of 3.6
million/Kg and by IBW of 4.2 million/Kg. Similarly, for failure to
engraft platelets by day 30 the cutoffs were 2.89 million/Kg by
ABW and 3.77 million/kg by IBW. Among the individuals with
ABW more than 25% of IBW(n122, 40%), we calculated the
optimal total CD34 dose required and compared to the actual dose
infused using both cutoffs (286 million vs. 446 million, P  0.001
using ANC cutoff and 251 million vs. 446 million using the platelet
cutoff, P 0.001). The PFS and OS post transplant was similar for
patients with BMI over 30 kg/m2 compared to those below this
cutoff. There was no difference when patients with myeloma or
lymphoma were studied separately.
Conclusion: This study conﬁrms prior studies that IBW deter-
mined stem cell dose is comparable to that by ABW. In patients
signiﬁcantly above IBW, it is reasonable to use a target based on
IBW which will allow for collection of less CD34 cells. In SCT
using corrected IBW does not compromise outcomes.
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POOR OUTCOME OF AUTOLOGOUS-BONE MARROW TRANSPLANT
(AUTO-BMT) FOLLOWING FAILED PERIPHERAL BLOOD STEM CELL
(PBSC) MOBILIZATION
Strickland, S.A.1, Chen, H.2, Hunt, C.1, Chinratanalab, W.1,
Engelhardt, B.1, Goodman, S.A.1, Greer, J.P.1, Kassim, A.A.1,
Morgan, D.S.1, Ruffner, K.L.1, Schuening, F.G.1, Jagasia, M.H.1
1Vanderbilt University Medical Center, Department of Medicine, Divi-
sion of Hematology/Oncology, Nashville, TN; 2Vanderbilt University
Medical Center, Department of Biostatistics, Nashville, TN.
BACKGROUND: Auto-PBSC transplant has replaced auto-
BMT. 10-30% of patients (pts) fail to mobilize adequate PBSCs.
Auto-BMT is typically considered in these pts. The results of such
an approach are not well studied.
METHODS: Consecutive pts undergoing high-dose chemother-
apy (HDC) and auto-BMT after failed PBSC mobilization were
evaluated. Nucleated cell (NC) dose, CD34 cell dose, time to
neutrophil (ANC) and platelet (Plt) engraftment were reviewed.
Overall survival (OS) and progression free survival (PFS) were
evaluated.
RESULTS: 22 pts failed to mobilize PBSCs and underwent
marrow harvest followed by HDC and auto-BMT from 2001 to
2006. 3 and 19 pts failed G-CSF and cyclophosphamide/G-CSF
mobilization. The median age was 56 yrs (range, 9-69). Diagnoses
included Non-Hodgkin lymphoma (14,64%), Hodgkin lymphoma
(4,18%), and acute myeloid leukemia (3,14%). The median num-
ber of salvage regimens before attempted PBSC mobilization was
1 (range, 0-4). The median NC and CD34 cell doses of the
marrow infused were 3.7108/kg (range, 1.4-6.8) and 1.0106/kg
(range, 0.3-3.0). All pts achieved ANC engraftment with G-CSF
support at a median of 20.5 days (range, 13-43). 55% (12/22) of the
pts achieved Plt engraftment at a median of 46.5 days (range,
23-92). The NC and CD34 cell dose did not differ signiﬁcantly
in patients with ANC engraftment (20 days or 20 days), Plt
engraftment (45 days or 45 days) or number of salvage regimens
( 1 or 1). There was no correlation between NC dose or
CD34cell dose and time to either ANC engraftment (NC, rho-
0.05, P0.8; CD34, rho-0.2, P0.4) or Plt engraftment
(NC,rho0.6, P0.9; CD34, rho- 0.2, P0.4).Median follow up
was 322 days (range, 53 to 1700). 59% (13/22) patients have
relapsed at a median of 155 days (range, 13-882). Median overall
survival (OS) and median PFS were 1140 and 509 days (95% CI,
368 to 649). Overall mortality was 36% (8/22). Causes of death
were progressive disease (6/8,75%) and treatment related mortality
(2/8,25%). 9/22 (41%) pts are alive without post-transplant relapse
(PTR) at a median follow-up time of 276 (range, 53 to 649). 6 of
these 9 pts continue to have Plt counts 100109/L.
CONCLUSIONS: The relapse rate after auto-BMT in pts who
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